Role of vericiguat in management of patients with heart failure with reduced ejection fraction after worsening episode

Worsening heart failure (HF) is a vulnerable period in which the patient has a markedly high risk of death or HF hospitalization (up to 10% and 30%, respectively, within the first weeks after episode). The prognosis of HF patients can be improved through a comprehensive approach that considers the d...

Descripción completa

Detalles Bibliográficos
Autores: Olivella, Aleix|||0000-0003-4912-2343, Almenar Bonet, Luis|||0000-0002-7710-361X, Moliner, P.|||0000-0002-5511-8597, Coloma, Emmanuel, Martinez Rubio, Antoni|||0000-0002-2070-4617, Paz Bermejo, Marco, Boixeda, Ramon, Cediel, Germán|||0000-0001-9667-7507, Méndez Fernández, Ana Belén, Facila Rubio, Lorenzo|||0000-0003-1402-4364
Tipo de recurso: artículo
Fecha de publicación:2023
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:294994
Acceso en línea:https://ddd.uab.cat/record/294994
https://dx.doi.org/urn:doi:10.1002/ehf2.14647
Access Level:acceso abierto
Palabra clave:Heart failure
Sacubitril-valsartan
SGLT2
Vericiguat
Worsening
id ES_ebbc4faf3d1604493a33f59ea4a1407f
oai_identifier_str oai:ddd.uab.cat:294994
network_acronym_str ES
network_name_str España
repository_id_str
spelling Role of vericiguat in management of patients with heart failure with reduced ejection fraction after worsening episodeOlivella, Aleix|||0000-0003-4912-2343Almenar Bonet, Luis|||0000-0002-7710-361XMoliner, P.|||0000-0002-5511-8597Coloma, EmmanuelMartinez Rubio, Antoni|||0000-0002-2070-4617Paz Bermejo, MarcoBoixeda, RamonCediel, Germán|||0000-0001-9667-7507Méndez Fernández, Ana BelénFacila Rubio, Lorenzo|||0000-0003-1402-4364Heart failureSacubitril-valsartanSGLT2VericiguatWorseningWorsening heart failure (HF) is a vulnerable period in which the patient has a markedly high risk of death or HF hospitalization (up to 10% and 30%, respectively, within the first weeks after episode). The prognosis of HF patients can be improved through a comprehensive approach that considers the different neurohormonal systems, with the early introduction and optimization of the quadruple therapy with sacubitril-valsartan, beta-blockers, mineralocorticoid receptor antagonists, and inhibitors. Despite that, there is a residual risk that is not targeted with these therapies. Currently, it is recognized that the cyclic guanosine monophosphate deficiency has a negative direct impact on the pathogenesis of HF, and vericiguat, an oral stimulator of soluble guanylate cyclase, can restore this pathway. The effect of vericiguat has been explored in the VICTORIA study, the largest chronic HF clinical trial that has mainly focused on patients with recent worsening HF, evidencing a significant 10% risk reduction of the primary composite endpoint of cardiovascular death or HF hospitalization (number needed to treat 24), after adding vericiguat to standard therapy. This benefit was independent of background HF therapy. Therefore, optimization of treatment should be performed as earlier as possible, particularly within vulnerable periods, considering also the use of vericiguat. 22023-01-0120232023-01-01Articlehttp://purl.org/coar/resource_type/c_6501VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttps://ddd.uab.cat/record/294994https://dx.doi.org/urn:doi:10.1002/ehf2.14647reponame:Dipòsit Digital de Documents de la UABinstname:Universitat Autònoma de BarcelonaInglésengopen accesshttp://purl.org/coar/access_right/c_abf2Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.https://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccessoai:ddd.uab.cat:2949942026-06-06T12:50:31Z
dc.title.none.fl_str_mv Role of vericiguat in management of patients with heart failure with reduced ejection fraction after worsening episode
title Role of vericiguat in management of patients with heart failure with reduced ejection fraction after worsening episode
spellingShingle Role of vericiguat in management of patients with heart failure with reduced ejection fraction after worsening episode
Olivella, Aleix|||0000-0003-4912-2343
Heart failure
Sacubitril-valsartan
SGLT2
Vericiguat
Worsening
title_short Role of vericiguat in management of patients with heart failure with reduced ejection fraction after worsening episode
title_full Role of vericiguat in management of patients with heart failure with reduced ejection fraction after worsening episode
title_fullStr Role of vericiguat in management of patients with heart failure with reduced ejection fraction after worsening episode
title_full_unstemmed Role of vericiguat in management of patients with heart failure with reduced ejection fraction after worsening episode
title_sort Role of vericiguat in management of patients with heart failure with reduced ejection fraction after worsening episode
dc.creator.none.fl_str_mv Olivella, Aleix|||0000-0003-4912-2343
Almenar Bonet, Luis|||0000-0002-7710-361X
Moliner, P.|||0000-0002-5511-8597
Coloma, Emmanuel
Martinez Rubio, Antoni|||0000-0002-2070-4617
Paz Bermejo, Marco
Boixeda, Ramon
Cediel, Germán|||0000-0001-9667-7507
Méndez Fernández, Ana Belén
Facila Rubio, Lorenzo|||0000-0003-1402-4364
author Olivella, Aleix|||0000-0003-4912-2343
author_facet Olivella, Aleix|||0000-0003-4912-2343
Almenar Bonet, Luis|||0000-0002-7710-361X
Moliner, P.|||0000-0002-5511-8597
Coloma, Emmanuel
Martinez Rubio, Antoni|||0000-0002-2070-4617
Paz Bermejo, Marco
Boixeda, Ramon
Cediel, Germán|||0000-0001-9667-7507
Méndez Fernández, Ana Belén
Facila Rubio, Lorenzo|||0000-0003-1402-4364
author_role author
author2 Almenar Bonet, Luis|||0000-0002-7710-361X
Moliner, P.|||0000-0002-5511-8597
Coloma, Emmanuel
Martinez Rubio, Antoni|||0000-0002-2070-4617
Paz Bermejo, Marco
Boixeda, Ramon
Cediel, Germán|||0000-0001-9667-7507
Méndez Fernández, Ana Belén
Facila Rubio, Lorenzo|||0000-0003-1402-4364
author2_role author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Heart failure
Sacubitril-valsartan
SGLT2
Vericiguat
Worsening
topic Heart failure
Sacubitril-valsartan
SGLT2
Vericiguat
Worsening
description Worsening heart failure (HF) is a vulnerable period in which the patient has a markedly high risk of death or HF hospitalization (up to 10% and 30%, respectively, within the first weeks after episode). The prognosis of HF patients can be improved through a comprehensive approach that considers the different neurohormonal systems, with the early introduction and optimization of the quadruple therapy with sacubitril-valsartan, beta-blockers, mineralocorticoid receptor antagonists, and inhibitors. Despite that, there is a residual risk that is not targeted with these therapies. Currently, it is recognized that the cyclic guanosine monophosphate deficiency has a negative direct impact on the pathogenesis of HF, and vericiguat, an oral stimulator of soluble guanylate cyclase, can restore this pathway. The effect of vericiguat has been explored in the VICTORIA study, the largest chronic HF clinical trial that has mainly focused on patients with recent worsening HF, evidencing a significant 10% risk reduction of the primary composite endpoint of cardiovascular death or HF hospitalization (number needed to treat 24), after adding vericiguat to standard therapy. This benefit was independent of background HF therapy. Therefore, optimization of treatment should be performed as earlier as possible, particularly within vulnerable periods, considering also the use of vericiguat.
publishDate 2023
dc.date.none.fl_str_mv 2
2023-01-01
2023
2023-01-01
dc.type.none.fl_str_mv Article
http://purl.org/coar/resource_type/c_6501
VoR
http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://ddd.uab.cat/record/294994
https://dx.doi.org/urn:doi:10.1002/ehf2.14647
url https://ddd.uab.cat/record/294994
https://dx.doi.org/urn:doi:10.1002/ehf2.14647
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by-nc-nd/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Dipòsit Digital de Documents de la UAB
instname:Universitat Autònoma de Barcelona
instname_str Universitat Autònoma de Barcelona
reponame_str Dipòsit Digital de Documents de la UAB
collection Dipòsit Digital de Documents de la UAB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869423253414477824
score 15,81155

Similares en LA Referencia